Antibodies deplete cancer cells in mice and human cell lines; reach previously inaccessible targets – EurekAlert

Three studies – one each in Science, Science Translational Medicine, and Science Immunology – reveal the promise of newly engineered bispecific antibodies, including by demonstrating their power against previously inaccessible tumor cell targets for the first time, in two cases. These bispecific antibodies, which simultaneously bind to tumor antigens and T cells, cleared cancer cells without damaging healthy cells in mouse tumor models and/or cell culture experiments, across the three studies. The…

Click here to view the original article.